On 31 August 2026, South Korean-headquartered Huonslab, a subsidiary of Huons Global, announced that it secured patent registration in Korea, and has filed an international patent application under the Patent Cooperation Treaty (PCT), for its recombinant human-derived hyaluronidase-based formulation conversion platform technology (HyDIFFUZE™), applied to 11 antibody therapeutics.
The antibody formulations to which the HyDIFFUZE™ technology has been applied by Huonslab are pembrolizumab, bevacizumab, isatuximab, durvalumab, cetuximab, risankizumab, dupilumab, obinutuzumab, ramucirumab, donanemab and dostarlimab.
Huonslab was established in 2018 and focuses on the development of innovative drug delivery technologies. It has a pipeline of biopharmaceutical and peptide drugs, including an early stage denosumab biosimilar, HLB3-013, in addition to its HyDIFFUZE™ technology that uses hyaluronidase to convert intravenous formulations of antibody drugs into subcutaneous injections.
Interest in subcutaneous formulations of antibody drug products is continuing to increase. MSD is currently engaged in litigation with Halozyme in the US and Europe in relation to Halozyme’s MDASE subcutaneous delivery technology and subcutaneous Keytruda® (pembrolizumab). A collaboration between Sandoz and Shanghai Henlius Biotech announced earlier in August 2026 provides Sandoz with an option for a recombinant human hyaluronidase (HLXTE-Haase1001) to be used in the development of a subcutaneously administered biosimilar. At the end of July 2026, it was announced that Celltrion is partnering with Korean-based G2GBIO to convert antibody drugs to subcutaneous formulations. Alteogen has partnered with a number of companies for the use of its ALT-B4 technology in subcutaneous formulations, including Sanofi, Daiichi Sankyo, and GSK.